OR WAIT null SECS
CHARLESTON, S.C. -- The 11th Annual International
Symposium on Staphylococci and Staphylococcal Infections (ISSSI) will be held at the North Charleston Convention Center in Charleston, S.C. Oct. 24-27, 2004, uniting the world's most respected scientists and
clinicians as they share research findings, new treatments, and strategies to combat what is becoming a worldwide public health crisis.
Studies by the Centers for Disease Control and Prevention (CDC), universities, and various agencies worldwide have shown a recent surge in the number of methicillin-resistant Staphylococcus aureus (MRSA) cases in the community without the presence of any known risk factors. Previously, the majority of
staphylococcal infections were traced to exposure to risk factors such as recent hospitalization or residence in a long-term care facility.
"Staphylococcus aureus has been increasing in frequency and severity both in the hospital and the community. Over the past six months, my clinic and consult service have seen more cases of S. aureus infections than ever before
in my 34 years of practice," reports Dr. Richard Proctor, professor of
medicine and medical microbiology/immunology at the University of Wisconsin Medical School and ISSSI faculty member.
Within the field of infectious diseases there is an increasingly relevant concern regarding emerging infections with the major staphylococcus, Staphylococcus aureus, and its resistant type, MRSA. A growing number of MRSA cases are resistant to one of the few available alternative antibiotics,
vancomycin. Another ISSSI faculty member, Dr. Keiichi Hiramatsu of the Department of Bacteriology of the Juntendo University, states, "Now the U.S.
has experienced the emergence of three VRSA (vancomycin-resistant MRSA)
strains to which the most trusted antibiotic vancomycin is just nothing more
than 'table salt.'" This trend of community-acquired MRSA infections and the
growth of vancomycin-resistant strains of MRSA creates an urgent need for new
approaches and treatments.
"Everyone is united by the goal of finding better solutions to fight these
increasingly powerful bacteria," says Dr. Joseph John, Jr., president of the
International Symposium on Staphylococci & Staphylococcal Infections, in
reference to ISSSI presenting a unique opportunity for respected leaders to
present new data on staphylococcal bacteremia, endocarditis, osteomyelitis,
device-related infections, and emerging syndromes. John is chief of the
medical service at the Ralph H. Johnson Veterans Affairs Medical Center and
professor of infectious diseases at the Medical University of South Carolina
This four-day meeting, held for the first time in the Americas, consists
of 11 plenary sessions with at least 40 lectures in the following areas:
staphylococcal genome, global epidemiology, emerging clinical syndromes,
staphylococcal pathogenesis, colonization & vaccines, multi-drug resistance,
infection control, new therapeutic agents, and community acquired MRSA.
Numerous international experts in various areas of staphylococcal infections
will address what Proctor terms as "one of the most serious challenges to
health in the developed world."
This activity is approved for AMA PRA credit. To register for this event
or obtain more information about the 11th Annual International Symposium on
Staphylococci & Staphylococcal Infections, visit http://www.isssi.org.
Source: International Symposium on Staphylococci and